DNLI / Denali: Need Patient Data To Justify That High Valuation

Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen. more_horizontal

Denali Therapeutics Inc. (DNLI) came out with quarterly earnings of $1.30 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share more_horizontal

Denali Therapeutics is a promising underdog in the biotech sector, focusing on neurodegenerative diseases, with significant investments in scientific more_horizontal

Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson's unique strategy to d more_horizontal

Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome). more_horizontal

Denali released first-quarter earnings last week. The company focuses on therapies to treat neurodegenerative diseases and has a relatively deep pipel more_horizontal

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates. more_horizontal

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compare more_horizontal